nach oben

Erschienen in:

01.08.2008 | Original Article

High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations

verfasst von: Killian P. O’Rourke, G. O’Donoghue, C. Adams, H. Mulcahy, C. Molloy, C. Silke, M. Molloy, F. Shanahan, F. O’Gara

Erschienen in: Rheumatology International | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Lymphotoxin-Beta (LT-Beta) is implicated in lymphoid follicle development, production of pro-inflammatory cytokines, and can enhance the proliferation of fibroblasts and synoviocytes. The objective of this study was to investigate LT-Beta and LT-BetaReceptor (LT-BetaR) gene expression in RA patient synovium and blood samples compared with control individuals, and correlate with LT-Alpha and TNF-Alpha gene expression and disease parameters. RT-PCR was used to investigate the gene expression of LT-Beta, LT-BetaR, TNF-Alpha and LT-Alpha in the blood and synovium of RA patients and a control group of individuals. LT-Beta gene expression was significantly higher in RA patient synovium compared to control synovium (P = 0.005). There was a significant positive correlation between LT-Beta and LT-Alpha gene expression in both the synovium (P = 0.001) and blood (P = 0.002) of RA patients. LT-Beta gene expression was significantly higher in RA patient synovial samples that were inflamed to a moderately severe degree compared to those inflamed to a minimal degree (P = 0.02). Analysis of clinical variables revealed a significant positive correlation between LT-BetaR gene expression in RA patient synovium and Pain VAS Score (P = 0.01) and also HAQ Score (P = 0.01). Increased LT-Beta gene expression occurs in RA synovium and correlates with the degree of inflammation. LT-Beta may play a role in RA disease pathogenesis by contributing to a more intense inflammatory reaction in the synovium.

Seldin MF, Amos CI, Ward R, Gregersen PK (1999) The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 42:1071–1079PubMedCrossRef

Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397–440PubMedCrossRef

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of Etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. NEJM 340:253–259PubMedCrossRef

Browning JL, Ngam-ek A, Lawton P, DeMarinis J, Tizard R, Chow EP et al (1993) Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 26:847–856CrossRef

Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL (2002) Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, Lymphotoxin-[alpha]1[beta]2, fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 168:1831–1839PubMed

Agyekum S, Church A, Sohail M, Krausz T, Van Noorden S, Polak J et al (2003) Expression of lymphotoxin-beta (LT-Beta) in chronic inflammatory conditions. J Pathol 199:115–21PubMedCrossRef

Shlopov BV, Gumanovskaya ML, Hasty KA (2000) Autocrine regulation of collagenase 3 (Matrix Metallo Proteinase 13) during osteoarthritis. Arthritis Rheum 43:195–205PubMedCrossRef

Mackay F, Majeau GR, Hochman PS, Browning JL. (1996) Lymphotoxin beta receptor triggering induces activation of the nuclear factor kappaB transcription factor in some cell types. J Biol Chem 271:24934–8PubMedCrossRef

Mulcahy B, Waldron-Lynch F, McDermott MF, Adams C, Amos CI, Zhu DK, Ward RH, Clegg DO, Shanahan F, Molloy MG, O’Gara F (1996) Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 59(3):676–683PubMed

10.

Newton JL, Harney SM, Wordsworth BP, Brown MA (2004) A review of the MHC genetics of rheumatoid arthritis. Genes Immun 5:151–157PubMedCrossRef

11.

Mandik-Nayak L, Wipke BT, Shih FF, Unanue ER, Allen PM (2002) Despite ubiquitous autoantigen expression arthrogenic autoantibody response initiates in the local lymph node. PNAS 99:14368–14373PubMedCrossRef

12.

Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O`Fallon WM et al (2001) Lymphoid neogenesis in rheumatoid synovitis. J Immunol 167:1072–1080PubMed

13.

Rennert PD, James D, Mackay F, Browning JL, Hochman PS (1998) Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 9:71–79PubMedCrossRef

14.

Ramey DR, Raynaud JP, Fries JF (1992) The health assessment questionnaire 1992: status and review. Arthritis Care Res 5:119–129PubMedCrossRef

15.

Anderson JJ, Chernoff MC (1993) Sensitivity to change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol 20:535–537PubMed

16.

Young CL, Adamson TC, Vaughan JH, Fox RI (1984) Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis. Arthritis Rheum 27:32–39PubMedCrossRef

17.

Krenn V, Souto-Carneiro MM, Kim HJ, Berek C, Starostik P, Konig A et al (2000) Hitopathology and molecular pathology of synovial B-lymphocytes in rheumatoid arthritis. Histol Histopathol 15:791–798PubMed

18.

Koizumi F, Matsuno H, Wakaki K, Ishii Y, Kurashige Y, Nakamura H (1999) Synovitis in rheumatoid arthritis: scoring of characteristic histopathological features. Pathol Int 49:298–304PubMedCrossRef

19.

Raff T, Van der Giet M, Endemann D, Wiederholt T, Paul M (1997) Design and testing of beta-actin primers for RT-PCR that do not co-amplify pseudogenes. Biotechniques 23:456–460PubMed

20.

Braun A, Takemura S, Vallejo AN, Goronzy JJ, Weyand CM (2004) Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 50:2140–2150PubMedCrossRef

21.

Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD et al (2000) A Chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406:309–314PubMedCrossRef

22.

Feldmann M, Andreakos E, Smith C, Bondeson J, Yoshimura S, Kiriakidis S et al (2002) Is NFkB a useful therapeutic target in rheumatoid arthritis. Ann Rheum Dis 61(Suppl 2):13–18

23.

Kuprash DV, Osipovich OA, Pokholok DK, Alimzhanov MB, Biragyn A, Turetskaya RL et al (1996) Functional analysis of the lymphotoxin-B promoter. J Immunol 156:2465–2472PubMed

24.

Voon DC, Subrata LS, Abraham LJ (2001) Regulation of lymphotoxin-beta by tumor necrosis factor, phorbol myristate acetate, and ionomycin in Jurkat T cells. J Interferon Cytokine Res 21:921–930PubMedCrossRef

25.

Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA (1990) Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 33:542–552PubMedCrossRef

26.

Thomson BM, Mundy GR, Chambers TJ (1987) Tumour necrosis factor alpha and beta induce osteoblastic cells to stimulate osteoclast bone resorption. J Immunol 138:775–779PubMed

27.

Kowanko IC, Bates EJ, Ferrante A (1988) Tumour necrosis factor-beta modulates human neutrophil-mediated cartilage damage. Scand J Immunol 28:591–598PubMedCrossRef

28.

Kuprash DV, Boitchenko VE, Yarovinsky FO, Rice NR, Nordheim A, Ruhlmann A et al (2002) Cyclosporin A blocks the expression of lymphotoxin alpha, but not lymphotoxin beta in human peripheral blood mononuclear cells. Blood 100:1721–1727PubMed

29.

Ettinger R (2000) The role of tumour necrosis factor and lymphotoxin in lymphoid organ development. Curr Top Microbiol Immunol 251:203–210PubMed

30.

Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell B (2001) NK-kB-inducing kinase is dispensible for activation of NF-kB in inflammatory settings but essential for lymphotoxin B receptor activation of NFkB in primary human fibroblasts. J Immunol 167:5895–5903PubMed

31.

Husson H, Lugli SM, Ghia P, Cardosso A, Roth A, Brohmi K et al (2000) Functional effects of TNF and lymphotoxin alpha1beta2 on FDC-like cells. Cell Immunol 203:134–143PubMedCrossRef

32.

Arend WP, Dayer J-M (1990) Cytokine and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33:305–315PubMedCrossRef

33.

Drouet C, Shahhov AN, Jongeneel CV (1991) Enhancers and transcription factors controlling inducibility of the tumor necrosis factor-alpha promoter in primary macrophages. J Immunol 147:1694–1700PubMed

34.

Kidd B (2004) What lessons can we learn from the study of pain pathways in rheumatic disease? J RCPE 34:66–67

35.

Wu Q, Saloman B, Chen M, Wang Y, Hoffman LM, Bluestone JA et al (2001) Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med 193:1327–1332PubMedCrossRef

36.

Mackay F, Browning JL, Lawton P, Shah SA, Comiskey M, Bhan AK et al (1998) Both the lymphotoxin and tumour necrosis pathways are involved in experimental murine models of colitis. Gastroenterology 115:1464–1475PubMedCrossRef

37.

Tamada K, Tamura H, Flies D, Fu YX, Celis E, Pease LR et al (2002) Blockage of LIGHT / Ltbeta and CD 40 signalling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 109:549–557PubMed

Titel: High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations
verfasst von: Killian P. O’Rourke
G. O’Donoghue
C. Adams
H. Mulcahy
C. Molloy
C. Silke
M. Molloy
F. Shanahan
F. O’Gara
Publikationsdatum: 01.08.2008
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 10/2008
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0574-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2008

Can Islamic prayers benefit spondyloarthritides? Case report of a patient with ankylosing spondylitis and increased spinal mobility after an intensive regimen of Islamic prayer

Polyarthritis induced by nonepisodic angioedema associated with eosinophilia

Management of cutaneous vascular complications in systemic scleroderma: experience from the German network

Catalase −262C>T polymorphism in systemic lupus erythematosus in Poland

Effects of pulsed and sinusoid electromagnetic fields on human chondrocytes cultivated in a collagen matrix